/FTRE
FTRE Stock - Fortrea Holdings Inc.
Healthcare|BiotechnologyNASDAQ
$17.74+6.80%
+$1.13 (+6.80%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.50
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-28.1%upside
Target: $12.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FTRE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.56 – $17.92
TARGET (TP)$12.75
STOP LOSS$16.32
RISK/REWARD1:-3.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.74
52W High$20.26
52W Low$3.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.70B | $2.84B | $2.84B | $3.06B | $2.58B |
| Gross Profit | $534.20M | $590.60M | $724.40M | $604.40M | $489.10M |
| Gross Margin | 19.8% | 20.8% | 25.5% | 19.8% | 19.0% |
| Operating Income | $-161,900,000 | $32.00M | $187.10M | $114.30M | $-314,200,000 |
| Net Income | $-328,500,000 | $-25,200,000 | $186.20M | $98.00M | $-359,200,000 |
| Net Margin | -12.2% | -0.9% | 6.6% | 3.2% | -13.9% |
| EPS | $-3.67 | $-0.04 | $2.11 | $1.11 | $-4.06 |
Company Overview
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
26%
Hold / Neutral
13
68%
Sell / Underperform
1
5%
Analyst Consensus🔴 Bearish
5 Bullish14 Neutral/Bearish
Price Targets
$27
Average Target
↑ 52.4% Upside
Now
$6
Low
$27
Average
$44
High
Based on 23 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Barclays | Upgrade | Equal Weight | $15 |
| December 11th 2025 | Citigroup | Upgrade | Buy | $21 |
| August 4th 2025 | Robert W. Baird | Upgrade | Outperform | $9 |
| May 2nd 2025 | Truist | Initiation | Hold | $7 |
| April 10th 2025 | Barclays | Downgrade | Underweight | $6 |
| December 11th 2024 | Citigroup | Downgrade | Neutral | $23← $30 |
| December 6th 2024 | Robert W. Baird | Downgrade | Neutral | $25← $28 |
| September 25th 2024 | Jefferies | Downgrade | Hold | $21← $25 |
| August 8th 2024 | Evercore ISI | Downgrade | In-line | $27← $31 |
| July 24th 2024 | Barclays | Resumed | Equal Weight | $30 |
| June 6th 2024 | Goldman | Initiation | Neutral | $28 |
| May 29th 2024 | TD Cowen | Initiation | Hold | $27 |
| May 28th 2024 | Mizuho | Initiation | Neutral | $27 |
| March 22nd 2024 | Robert W. Baird | Initiation | Neutral | $43 |
| March 6th 2024 | Deutsche Bank | Initiation | Hold | $36 |
Earnings History & Surprises
FTREBeat Rate
40%
Last 10 quarters
Avg Surprise
-45.8%
EPS vs Estimate
Beats / Misses
4/6
Last 12 quarters
Latest EPS
$0.12
Q4 2025
EPS Surprise History
Q1 24
-17.4%
$0.19vs$0.23
Q2 24
-619.4%
$-0.04vs$-0.01
Q3 24
-142.9%
$-0.03vs$0.07
Q4 24
-14.8%
$0.23vs$0.27
Q1 25
-50.0%
$0.18vs$0.36
Q2 25
+128.6%
$0.02vs$-0.07
Q3 25
+216.7%
$0.19vs$0.06
Q4 25
-25.0%
$0.12vs$0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $0.16 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.16 | $0.12 | -25.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $0.06 | $0.19 | +216.7% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.07 | $0.02 | +128.6% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $0.36 | $0.18 | -50.0% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $0.27 | $0.23 | -14.8% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $0.07 | $-0.03 | -142.9% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.01 | $-0.04 | -619.4% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $0.23 | $0.19 | -17.4% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $0.18 | $0.24 | +33.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $0.39 | $0.52 | +33.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-0.13 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.45 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.69 | — | — |
Q2 2022 | Jun 29, 2022 | — | $0.75 | — | — |
Q1 2022 | Mar 30, 2022 | — | $0.37 | — | — |
Latest News
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $13
➖ NeutralBenzinga•Dec 18, 2025, 01:14 PM
Barclays Upgrades Fortrea Holdings to Equal-Weight, Raises Price Target to $15
📈 PositiveBenzinga•Dec 15, 2025, 01:50 PM•Also:
Citigroup Upgrades Fortrea Holdings to Buy, Raises Price Target to $21
📈 PositiveBenzinga•Dec 11, 2025, 02:06 PM•Also:
SCTbio And Fortrea Collaborate To Streamline Development, Accelerate Timelines And Bring Advanced Therapies To Patients Faster
📈 PositiveBenzinga•Dec 4, 2025, 12:03 PM
Fortrea Completes $75.7M Debt Tender Offer, Reducing 7.500% Senior Secured Notes Due 2030 To $494.3M Following Business Divestiture
📈 PositiveBenzinga•Nov 24, 2025, 12:12 PM
Barclays Maintains Underweight on Fortrea Holdings, Raises Price Target to $10
➖ NeutralBenzinga•Nov 6, 2025, 02:42 PM•Also:
Fortrea Holdings shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 5, 2025, 05:33 PM
Fortrea Holdings Raises FY2025 Sales Guidance from $2.600B-$2.700B to $2.700B-$2.750B vs $2.656B Est
📈 PositiveBenzinga•Nov 5, 2025, 11:31 AM
Fortrea Holdings Q3 Adj. EPS $0.12 Misses $0.15 Estimate, Sales $701.300M Beat $647.734M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 11:31 AM
Fortrea Launches Tender Offer To Repurchase Up To $75.744M Of 7.500% Senior Secured Notes Due 2030
📈 PositiveBenzinga•Oct 20, 2025, 11:09 AM
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $9
➖ NeutralBenzinga•Oct 17, 2025, 01:18 PM
Evercore ISI Group Maintains In-Line on Fortrea Holdings, Raises Price Target to $11
📈 PositiveBenzinga•Oct 8, 2025, 01:13 PM
Jefferies Maintains Hold on Fortrea Holdings, Raises Price Target to $9.5
➖ NeutralBenzinga•Sep 9, 2025, 10:55 AM
Baird Maintains Outperform on Fortrea Holdings, Raises Price Target to $14
📈 PositiveBenzinga•Sep 3, 2025, 12:06 PM
Fortrea jumps 5% after naming Anshul Thakral as CEO
📈 PositiveSeeking Alpha•Jun 12, 2025, 09:13 AM
Frequently Asked Questions about FTRE
What is FTRE's current stock price?
Fortrea Holdings Inc. (FTRE) is currently trading at $17.74 per share. The stock has moved +6.80% today.
What is the analyst price target for FTRE?
The average analyst price target for FTRE is $12.75, based on 1 analyst.
What sector is Fortrea Holdings Inc. in?
Fortrea Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FTRE's market cap?
Fortrea Holdings Inc. has a market capitalization of $1.60 billion, making it a small-cap company.
Does FTRE pay dividends?
No, Fortrea Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to FTRE for comparison